AXSOME THERAPEUTICS INC (AXSM)

US05464T1043 - Common Stock

82.83  -1.72 (-2.03%)

After market: 82.65 -0.18 (-0.22%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AXSOME THERAPEUTICS INC

NASDAQ:AXSM (7/12/2024, 7:19:51 PM)

After market: 82.65 -0.18 (-0.22%)

82.83

-1.72 (-2.03%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-2.79%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap3.93B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AXSM Daily chart

Company Profile

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 383 full-time employees. The company went IPO on 2015-11-19. The firm is developing and delivering novel therapies for the central nervous system (CNS), conditions that have limited treatment options. The firm's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of the major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Its AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. Its AXS-07 is a multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Company Info

AXSOME THERAPEUTICS INC

One World Trade Center, 22Nd Floor

New York City NEW YORK 10038

P: 12123323241

CEO: Herriot Tabuteau

Employees: 383

Website: https://www.axsome.com/

AXSM News

News Image3 days ago - Axsome Therapeutics, Inc.Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
News Image3 days ago - Axsome Therapeutics, Inc.Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...

News Image5 days ago - Market News VideoNotable Monday Option Activity: SPOT, AXSM, HOOD
News Image8 days ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy in July 2024

For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024.

News Image9 days ago - InvestorPlace3 Undervalued Biotech Gems With 200%+ Analyst Price Targets

These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise.

News Image12 days ago - Market News VideoInteresting AXSM Put And Call Options For August 16th

AXSM Twits

Here you can normally see the latest stock twits on AXSM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example